[Overall Performance] Revenue: KRW 10.31T, Operating Profit: KRW 736B [Revenue] Decreased by KRW 661B (-6.0%) compared to KRW 10.971T in Q3 2023Decreased by KRW 695B (-6.3%) compared to KRW 11.005T in Q2 2024 [Operating Profit] Decreased by KRW 94B (-11.3%) compared to KRW 830B in Q3 2023Decreased by KRW 164B

[Overall Performance] Revenue: KRW 11.005T, Operating Profit: KRW 900B  [Revenue] Increased by KRW 419B (4.0%) compared to KRW 10.586T in Q2 2023 Increased by KRW 209B (1.9%) compared to KRW 10.796T in Q1 2024 [Operating Profit] Increased by KRW 128B (16.6%) compared to KRW 772B in Q2 2023 Increased by

Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”) announced today an investment into Flagship Pioneering Fund VIII (“Fund VIII”) to help fuel breakthrough innovations in human health and sustainability. In addition to the strategic partnership that Flagship Pioneering (hereinafter referred

Overall Performance Revenue: KRW 10.796T, Operating Profit: KRW 712B – Year-over-Year (YoY) comparison: Revenue increased by KRW 557B (5.4%) from KRW 10.239T in Q1 2023,operating profit increased by KRW 71B (11.1%) from KRW 641B in Q1 2023 – Quarter-over-Quarter (QoQ) comparison: Revenue increased by KRW 696B (6.9%) from KRW 10.100B

– 2023 revenue KRW 41.896T, operating profit KRW 2.870T – Highest possible dividend payout under consistent dividend policy at KRW 2,550 per common stock and KRW 2,600 per preferred stock – Cancellation of treasury shares – 7,807,563 common shares (third of those currently held), 159,835 preferred shares (all of those

With another New Year upon us, it’s a reminder of how quickly the world’s advancing as we seek to seize opportunities and negotiate challenges. It’s also a time when many of us reflect on the past year. Looking back on 2023 recalls memories that made the year special for our